Posted 9/6/2019 11:42 AM (GMT -6)
Multiple, simultaneous biologics is currently experimental. Nothing concrete about it yet, but it shows some promise and is an area currently being studied. Not sure how well your insurance would cover this, a point to ask as it is not standard clinical practice that most insurances expect.
Xeljanz, itself is not a cell surface antibody (rather it is a tiny inside the cell molecule). So stopping xeljanz cannot form antibodies against it (as remicade might).
Have you tried reintroducing mesalamine enemas or supporistories? That has worked well for me, in a similar scenario: well managed on a biologic with only occasional and limited rectal inflammation.